Physician profile
Bruce A Bouts
NPI 1164488268
$5,771.64
in general payments reported to CMS, 2019-2025
44 companies · $861 in 2025
The $861 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,077 · 2020: $437 · 2021: $406 · 2022: $746 · 2023: $1,088 · 2024: $1,157 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,106.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $825.07 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $744.90 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $456.73 | 2019-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.94 | 2022-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $305.72 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $268.03 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| E.R. Squibb & Sons, L.L.C. | $266.91 | 2019-2024 | Opdivo, Eliquis |
| Janssen Pharmaceuticals, INC | $246.26 | 2019-2021 | |
| Glaxosmithkline, LLC. | $236.72 | 2024-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $208.89 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $189.09 | 2019-2024 | |
| Dexcom, INC. | $172.20 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $167.89 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $161.16 | 2019-2025 | |
| Amgen INC. | $149.57 | 2022-2025 | Prolia, Evenity, Otezla |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Bouts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.